Open Orphan PLC Investor Event Attendance and Presentation (6721D)

TIDMORPH

RNS Number : 6721D

Open Orphan PLC

21 February 2020

21 February 2020

RNS REACH

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at ShareSoc Growth Company Seminar, Manchester

Open Orphan , the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, and has Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London, is pleased to announce that the Company will be attending and presenting at the ShareSoc Growth Company Seminar on February 25, 2020 at DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG .

Cathal Friel, Open Orphan's Executive Chairman will be presenting from 18:40 onwards to update existing and potential investors on the Company's business plans for 2020.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the acquisition of hVIVO and the potential for Open Orphan as it moves rapidly forward rapidly. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services ,and supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all of which are particularly relevant and topical in the environment of heightened awareness in light of the current outbreak of coronavirus disease (COVID-19).It also has Europe's only commercial 24 bed quarantine clinic and on site virology laboratory at Queen Mary's Hospital in London.

A link to our investor presentation is already available on our website at https://www.openorphan.com/sites/openorphan/files/Open_Orphan_Investor_Deck_0120_1.pdf

Additionally, a link to the video of Open Orphan's presentation will be made available on the Company website following the event.

For further information on the Shares Investor Evening and registration, please visit the event website https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-25-february-2020/

No new material information will be disclosed at this event.

Enquiries:

Open Orphan Plc Tel: [phone]

Cathal Friel, Executive Chairman [phone]

Trevor Phillips, Chief Executive Officer [phone]

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]

Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]

Tom Huddart / Billy Clegg / Daniel Sherwen

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.

Open Orphan comprises of two commercial specialist CRO services businesses (Venn and hVIVO) and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (c hemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAKZGZZNGKGGZM

(END) Dow Jones Newswires

February 21, 2020 02:00 ET (07:00 GMT)